home / stock / allr / allr news

ALLR News and Press, Allarity Therapeutics Inc. From 03/15/22

Stock Information
Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ
Website: allarity.com
Menu
ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLR - Allarity Therapeutics Provides Update on Dovitinib Program

FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s N...
ALLR - IRNT, FAT and DTSS among mid-day movers

Gainers: Indonesia (NYSE:INDO) +79%. Meritor (NYSE:MTOR) +45%. Ocugen (NASDAQ:OCGN) +22%. Datasea (NASDAQ:DTSS) +20%. IronNet (NYSE:IRNT) +20%. Riley Exploration Permian (NYSE:REPX) +19%. Arteris (NASDAQ:AIP) +17%. Houghton Mifflin Harcourt Company (NASDAQ:HMHC) +15%. MEDIROM Healthcare Techn...

ALLR - Allarity sinks after regulatory setbacks in U.S. for cancer drug

Allarity Therapeutics (ALLR -31.0%), a clinical-stage biopharmaceutical company, is trading sharply lower in morning hours on Tuesday after announcing a regulatory setback in the U.S. for its experimental therapy dovitinib and DRP-Dovitinib companion diagnostic. The U.S. Food and Drug Adminis...

ALLR - HOOKIPA, Nuvectis top healthcare gainers; Allarity, Homology Medicines lead losers' pack

Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...
ALLR - Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

Refusal to File letters concern the new drug application for d ovitinib and the DRP ® -Dovitinib companion diagnostic pre-market approval application Allarity intends to seek guidance from the FDA on how to further advance dovitinib ...

ALLR - Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers , utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug...

Previous 10 Next 10